Editor’s pick: Indapta Therapeutics
Technology tamfitronics Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Indapta Therapeutics is using a subset of natural killer cells found in healthy donors to supercharge monoclonal antibodies to fight cancer and autoimmune disease. Natural killer (NK) cells, the cytotoxic effector cells of the innate immune system, are attractive candidates for immunotherapy because of their ability to generally recognize and kill stressed cells, such as tumor cells and virus-infected cells. However, some NK cells are better killers than others, depending on their specific repertoire of inhibitory and activating receptors that bind to respective ligands on target cells. Indapta Therapeutics aims to harness the power of a subset of...